Compounds > bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine
Page last updated: 2024-12-10

bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: used for tumor therapy; structure given in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081807
MeSH IDM0196929

Synonyms (7)

Synonym
133063-13-5
iso-bosinc
bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon
silicon, bis(bis(2-methylpropyl)octadecylsilanolato)(37h,39h-tetranaphtho(2,3-b:2',3'-g:2'',3''-l:2''',3'''-q)porphyrazinato(2-)-n37,n38,n39,n40)-, (oc-6-12)-
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine
DTXSID70157934
bis(2-methylpropyl)-octadecyl-oxidosilane;2,15,28,41,53,54-hexaza-55,56-diazanidatridecacyclo[40.10.1.13,14.116,27.129,40.04,13.06,11.017,26.019,24.030,39.032,37.043,52.045,50]hexapentaconta-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29(54),30,32,34,36,38,40,42

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic behaviour and phototherapeutic effectiveness of bis(di-isobutyloctadecylsil-oxy)-2,3-naphthalocyanatosilicon (iso-BOSiNc) incorporated into dipalmitoyl-phosphatidylcholine (DPPC) liposomes have been studied in Balb/c mice bearing an MS-2 fibrosarcoma."( Liposome-delivered Si(IV)-naphthalocyanine as a photodynamic sensitiser for experimental tumours: pharmacokinetic and phototherapeutic studies.
Cuomo, V; Jori, G; Kenney, ME; Rihter, B; Rodgers, MA, 1990)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Neoplasms
[description not available]		02.3820
Bladder Cancer
[description not available]		01.9910
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		01.9910
B16 Melanoma
[description not available]		01.9910